A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial
Name:
36413792.pdf
Size:
1.436Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Mussai, F.De Santo, C.
Cheng, P.
Thomas, I. F.
Ariti, C.
Upton, L.
Scarpa, U.
Stavrou, V.
Sydenham, M.
Burnett, A. K.
Knapper, S. K.
Mehta, P.
McMullin, M. F.
Copland, M.
Russell, N. H.
Dennis, Michael
Affiliation
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UKIssue Date
2022
Metadata
Show full item recordAbstract
The survival of acute myeloid leukaemia (AML) patients aged over 60 has been suboptimal historically, whether they are treated using hypomethylating agents, low-dose cytarabine (LDAC) or venetoclax-based regimens. Progress is being made, however, for subgroups with favourable molecular or cytogenetic findings. Arginine metabolism plays a key role in AML pathophysiology. We report the only randomised study of LDAC with recombinant arginase BCT-100 versus LDAC alone in older AML patients unsuitable for intensive therapy. Eighty-three patients were randomised to the study. An overall response rate was seen in 19.5% (all complete remission [CR]) and 15% (7.5% each in CR and CR without evidence of adequate count recovery [CRi]) of patients in the LDAC+BCT-100 and LDAC arms respectively (odds ratio 0.73, confidence interval 0.23-2.33; p = 0.592). No significant difference in overall or median survival between treatment arms was seen. The addition of BCT-100 to LDAC was well tolerated.Citation
Mussai F, De Santo C, Cheng P, Thomas IF, Ariti C, Upton L, et al. A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial. British journal of haematology. 2022 Nov 22. PubMed PMID: 36413792. Epub 2022/11/23. eng.Journal
British Journal of HaematologyDOI
10.1111/bjh.18560PubMed ID
36413792Additional Links
https://dx.doi.org/10.1111/bjh.18560Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.18560